Listen to this article

U.S. affiliates of Parsippanny-based Teva Pharmaceutical announced May 2 that they reached an agreement with Lupin to resolve the dispute over that company’s abbreviated new drug application for a generic deutetrabenazine product.

According to the statement, Teva and Lupin have been involved in a patent infringement litigation in which the former asserted a number of patents against the latter that cover Teva’s Austedo tablets, which is the first and only U.S. Food and Drug Administration-approved product to treat both tardive dyskinesia in adults and chorea associated with Huntingdon’s disease.

Under the terms of the settlement, the litigation will end between the companies in the U.S. District Court of New Jersey, and Lupin will have a license to sell its generic product beginning April 2033, or earlier under certain circumstances.

“Teva believes that today’s settlement with Lupin is a further reflection of the strength of its intellectual property covering its AUSTEDO product,” the company said in a statement. Lupin could not immediately be reached for comment.

Teva added that, on March 9, the U.S. Patent Office Patent Trial and Appeal Board declined to institute a review of its patent for deutetrabenazine in response to a petition submitted by Apotex. Additionally, Teva said it will continue to pursue the patent infringement suit it brought against Aurobindo regarding Aurobindo’s abbreviated new drug application for a generic deutetrabenazine product.